SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently experiencing high volatility as investors weigh milestone euphoria against earnings anxiety, with market participants closely monitoring the company's progress on nuclear isotope licensing and Department of Energy approvals. Community discussions are centered on the upcoming business update, with traders debating whether these regulatory advancements will provide a significant catalyst or if the stock is being pumped ahead of potentially lackluster financial results.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive deal with Meta to provide AI infrastructure, with community members actively debating the company's valuation, capital requirements, and the impact of a subsequent $3.75 billion convertible debt offering. While many investors express long-term conviction in the firm's role as a neocloud leader, discussion remains polarized between those viewing the debt raise as essential fuel for hypergrowth and others expressing concern over immediate price volatility and dilution.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility during its Nasdaq debut, with investors debating the company's military-grade autonomous drone technology against concerns regarding its financial disclosures and typical IPO trading patterns. Market participants are actively tracking the stock's frequent trading halts while speculating on the long-term viability of its battlefield-tested software.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh its dominant position in the GLP-1 weight-loss market against intensifying competition and a recent high-profile clinical trial setback for its primary rival, Novo Nordisk. While the community is actively debating the timing of a potential oral drug launch, sentiment remains focused on the company's ability to maintain its market lead despite ongoing analyst downgrades and broader sector volatility.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors monitor the appointment of a new CFO and anticipate the potential announcement of a major hyperscaler tenant. While some community members remain skeptical of management's communication and deal timelines, others are optimistic that the company's behind-the-meter energy model will drive significant long-term growth as infrastructure demand for AI continues to rise.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is seeing intense volatility and active community debate as investors weigh strong earnings growth and AI infrastructure demand against market-wide profit-taking and valuation concerns. While many traders are buying the dip in anticipation of continued hyperscaler expansion, others remain cautious due to recent institutional selling and sector-wide sentiment shifts following major semiconductor conference announcements.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and heavy trading volume ahead of the upcoming Optical Fiber Communications Conference (OFC), as market participants speculate on potential major partnership announcements and purchase orders. Community sentiment remains polarized between long-term investors tracking institutional accumulation and technical alignment with hyperscale AI hardware, and skeptics voicing concerns over persistent pre-revenue status and reliance on strategic collaborations.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing significant volatility and trading activity as the market reacts to the launch of Uber Autonomous Solutions, a new platform bundling mapping, training data, and fleet operations to attract robotaxi developers. While some investors are bullish on the company's long-term pivot toward an asset-right model and autonomous infrastructure, others remain skeptical about increased capital expenditures and intensifying competition in the autonomous vehicle sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing active community discussion as traders monitor potential buyout interest and growth prospects for its MS therapy, BRIUMVI, ahead of the company's upcoming earnings call. Investors are focused on the firm's revenue trajectory, recent long-term clinical data, and the potential impact of share repurchases on stock performance.

Tencent Music Entertainment Group engages in the business of operating online music entertainment platforms to provide music streaming, online karaoke, and live streaming services. Its product brands include QQ Music, Kugou Music, Kuwo Music, and WeSing. The company was founded on June 6, 2012 and is headquartered in Shenzhen, China.

Tencent Music Entertainment Group - ADR

Tencent Music Entertainment Group

Tencent Music is drawing strong investor interest following robust quarterly results that featured significant revenue beats, margin expansion, and strong user growth. The community remains focused on the company's valuation relative to peers, its aggressive share buyback programs, and the potential for a continued breakout as technical indicators align with its improving fundamental performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the...

Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade

The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Prothena (NASDAQ:PRTA) Shares Up 8.7% - Still a Buy?

Prothena (NASDAQ:PRTA) Trading 8.7% Higher - Should You Buy...

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts

Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has earned a consensus rating of "Hold" from the eleven brokerages that are currently covering the firm, MarketBeat reports. Two equities...

Prothena To Buy Back Up To $100 Mln Of Shares

(RTTNews) - Prothena Corporation plc (PRTA) announced that its board has authorized a share repurchase plan allowing the company to buy back up to $100 million of its outstanding ordinary shares...

Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

FY2026 EPS Estimates for Prothena Boosted by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Prothena in a report released on Friday...

Prothena (NASDAQ:PRTA) Price Target Raised to $12.00

Royal Bank Of Canada lifted their target price on shares of Prothena from $11.00 to $12.00 and gave the stock a "sector perform" rating in a report on Friday...

Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus

PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.

Prothena Q4 Earnings Call Highlights

Prothena (NASDAQ:PRTA) used its fourth-quarter and full-year 2025 results call to highlight partner-driven clinical momentum, updates from its wholly owned preclinical portfolio, and a sharper cash...

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRTA News

PRTAProthena Corporation plc